PROQR THRAPEUTICS N V's ticker is PRQR and the CUSIP is N71542109. A total of 69 filers reported holding PROQR THRAPEUTICS N V in Q3 2021. The put-call ratio across all filers is 1.13 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $2,791,000 | -91.3% | 3,084,150 | -23.2% | 0.00% | -100.0% |
| Q4 2021 | $32,182,000 | -28.2% | 4,017,760 | -24.9% | 0.01% | -37.5% |
| Q3 2021 | $44,796,000 | +79.5% | 5,351,845 | +44.5% | 0.01% | +100.0% |
| Q2 2021 | $24,959,000 | +11.2% | 3,703,031 | +9.1% | 0.00% | 0.0% |
| Q1 2021 | $22,436,000 | +54.6% | 3,394,246 | -1.8% | 0.00% | +33.3% |
| Q4 2020 | $14,514,000 | -35.8% | 3,455,765 | -26.8% | 0.00% | -40.0% |
| Q3 2020 | $22,620,000 | -23.6% | 4,722,240 | -3.0% | 0.01% | -28.6% |
| Q2 2020 | $29,600,000 | +6.7% | 4,868,415 | -3.6% | 0.01% | 0.0% |
| Q1 2020 | $27,736,000 | -49.1% | 5,052,291 | -8.1% | 0.01% | -36.4% |
| Q4 2019 | $54,457,000 | +1242.0% | 5,495,128 | +679.9% | 0.01% | +1000.0% |
| Q3 2019 | $4,058,000 | +60.1% | 704,596 | +153.0% | 0.00% | 0.0% |
| Q2 2019 | $2,535,000 | – | 278,523 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aquilo Capital Management, LLC | 748,861 | $6,815,000 | 2.37% |
| Opus Point Partners Management, LLC | 138,461 | $1,260,000 | 1.86% |
| RTW INVESTMENTS, LP | 3,722,950 | $33,879,000 | 1.81% |
| Kerrisdale Advisers, LLC | 465,580 | $4,237,000 | 1.52% |
| DAFNA Capital Management LLC | 261,521 | $2,380,000 | 0.90% |
| SPHERA FUNDS MANAGEMENT LTD. | 470,000 | $4,277,000 | 0.58% |
| Artal Group S.A. | 1,300,000 | $11,830,000 | 0.48% |
| Orbimed Advisors | 1,382,502 | $12,581,000 | 0.20% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 56,000 | $511,000 | 0.19% |
| ALTRINSIC GLOBAL ADVISORS LLC | 201,360 | $1,832,000 | 0.08% |